| 201 |
15870831 | Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). | 2005 May 9 |
1 |
| 202 |
15947117 | Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. | 2005 Jun |
1 |
| 203 |
16009452 | Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. | 2005 Oct |
2 |
| 204 |
16023108 | ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. | 2005 Aug 1 |
1 |
| 205 |
16106023 | Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. | 2005 Aug 17 |
1 |
| 206 |
16322337 | Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. | 2005 Dec |
3 |
| 207 |
16373711 | Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. | 2005 Dec |
2 |
| 208 |
14760103 | ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. | 2004 Jan 15 |
1 |
| 209 |
15078990 | Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. | 2004 Apr |
3 |
| 210 |
15131063 | Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. | 2004 May 1 |
2 |
| 211 |
15258753 | Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. | 2004 Oct |
4 |
| 212 |
15269164 | Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. | 2004 Jul 15 |
2 |
| 213 |
15289342 | Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. | 2004 Aug 1 |
2 |
| 214 |
15292385 | Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. | 2004 Aug 4 |
6 |
| 215 |
15377841 | Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. | 2004 Sep |
1 |
| 216 |
15492241 | Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. | 2004 Oct 15 |
2 |
| 217 |
29793222 | The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. | 2004 Dec |
1 |
| 218 |
14555504 | Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. | 2003 Oct 1 |
1 |
| 219 |
14633703 | The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. | 2003 Nov 15 |
2 |